Revenue growth is modest but steady; focus on the Recordati partnership ramp in Europe and potential strategic alternatives. Cash position is strong, reducing bankruptcy risk. Monitor next quarter for sustained revenue growth and progress toward profitability.
AMRN drugs
AMRN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $14.29entry
- T+1 · 7mo ago −2.52%α −3.54% · $13.93
- T+5 · 7mo ago +4.27%α +1.16% · $14.90
- T+20 · 6mo ago +0.84%α −5.21% · $14.41
- T+60 · 4mo ago −5.18%α −9.29% · $13.55
Price Chart
How similar events traded
Executive Summary
Amarin reported Q1 2026 revenue of $45.1M (+7% YoY), beating the $43.8M consensus, but GAAP EPS was -$0.03, a significant miss vs the $0.17 estimate. Net loss narrowed to $10.5M from $15.7M a year ago, driven by cost cuts. The company reiterated full-year positive cash flow guidance but provided no top-line forecast.
Key Financial Metrics
Key Facts
- Q1 2026 total net revenue $45.1M, up 7% from $42.0M in Q1 2025
- GAAP net loss $(10.5)M or $(0.03) per share vs loss of $(15.7)M or $(0.04) in Q1 2025
- Operating expenses fell 31% to $29.1M, including $3.3M restructuring
- Cash and investments rose to $307.8M from $302.6M at Dec 2025; debt-free
- Reiterated expectation for positive cash flow for full year 2026
Financial Impact
Revenue beat consensus by ~3%; EPS miss of ~$0.20 vs consensus
Risk Factors
- Generic competition for VASCEPA in the US could pressure market share
- European sales transition to Recordati may cause near-term volatility
- Litigation settlements ($3.1M in Q1) may recur
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-188935 |
| Document: amrn-20260429.htm | 0001193125-26-188935 |
| Document: 0001193125-26-188935-index-headers.html | 0001193125-26-188935 |
| Document: 0001193125-26-188935-index.html | 0001193125-26-188935 |
| Document: 0001193125-26-188935.txt | 0001193125-26-188935 |
| 8-K Data (Synthetic) | 0001193125-26-188935 |
Track record
8 reports on AMRN
The track record builds as more bullish or bearish reports settle.
Filters
- Oct 28, 202619d ago 8-K Neutral 5/10 No price data
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $12.75 Now $11.31 −11.26% settles Jan 26
- Oct 25, 202622d ago Press Release Mixed 6/10 Entry $12.09 Now $11.31 −6.45% settles Jan 22
- Aug 28, 202611w ago Press Release Neutral 4/10 Entry $13.97 Now $11.31 −19.04% settles Nov 23
- Jun 4, 202623w ago Court Ruling Bearish 7/10 Entry $13.80 to $13.97 Now $11.31 +18.04% ▼ −1.23% +0.65% vs SPY
- Apr 29, 202628w ago 8-K Neutral 4/10 Viewing Entry $14.29 to $13.55 Now $11.31 −20.85% ▼ −5.18% −9.29% vs SPY
- Mar 16, 202635w ago Press Release Neutral 4/10 Entry $15.42 to $14.20 Now $11.31 −26.65% ▼ −7.91% −18.40% vs SPY
- Feb 25, 202637w ago 8-K Bearish 6/10 Entry $14.05 to $14.27 Now $11.31 +19.50% ▼ −1.57% +5.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers